Hip FracturesHIP ATTACKNCT02027896
HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial
A study testing Accelerated medical clearance and surgery in people with Hip Fractures, run by McMaster University at 69 sites in 17 countries.
Trial summary
HIP ATTACK is an international randomized controlled trial of 3000 patients with a hip fracture that requires a surgical intervention. This trial will determine the effect of accelerated medical clearance and accelerated surgery compared to standard care on the 90-day risk of mortality and major perioperative… Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Hip Fractures
- What is being tested?
- Accelerated medical clearance and surgery
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,001 participants
- Where
- 69 sitesin 17 countries
- Study dates
- 14 Mar 2014to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age ≥45 years; and
- diagnosis of hip fracture during working hours with a low-energy mechanism (i.e., falling from standing height) requiring surgery.
Who cannot join
- patients requiring emergent surgery or emergent interventions for another reason (e.g., subdural hematoma, abdominal pathology requiring urgent laparotomy, acute limb ischemia, other fractures or trauma requiring emergent surgery, necrotising fasciitis, coronary revascularization, pacemaker-implantation);
- open hip fracture;
- bilateral hip fractures;
- peri-prosthetic fracture;
- therapeutic anticoagulation not induced by a Vitamin K Antagonist, unfractionated heparin, (e.g., administration of therapeutic Low Molecular Weight Heparin (LMWH) (>6,000 u/24h) in the 24 hours prior to enrolment, or intake of any other non-reversible oral anticoagulant(s) for which there is no reversing agent available
- patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
- patients refusing participation; or
- patients previously enrolled in the study.
Trial locations and contacts
69 sites in 17 countries.
69 sites in 17 countries
Canada18 sites
Royal Victoria Hospital
Barrie, Ontario
South Health Campus
Calgary, Alberta
University of Alberta Hospital
Edmonton, Alberta
Etobicoke General Hospital
Etobicoke, Ontario
QEII Health Sciences
Halifax, Nova Scotia, B3H 3A7
St. Joseph's Hospital Hamilton
Hamilton, Ontario, L8N 4A6
Hamilton Health Sciences - Juravinski Hospital
Hamilton, Ontario, L8V 5C2
Kingston General Hospital
Kingston, Ontario, K7L 2V7
Grand River Hospital
Kitchener, Ontario
Victoria Hospital, London Health Sciences
London, Ontario
Markham Stouffville Hospital
Markham, Ontario
Ottawa General Hospital
Ottawa, Ontario, K1H 8L6
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, P7B 6V4
Humber River Hospital
Toronto, Ontario, M3M 0B2
St. Michael's Hospital
Toronto, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario
Vancouver General Hospital
Vancouver, British Columbia
Concordia Hip and Knee Institute
Winnipeg, Manitoba, MB R2K 2M9
India11 sites
Government TD Medical College
Alappuzha, 688005
Sparsh Hospital
Bangalore, 560099
PGIMER
Chandigarh
Bangalore Baptist Hospital
Hebbāl, 560024
NH Kolkata
Kolkata, 700099
CMC Ludhiana
Ludhiana, 141008
Seven Star Hospital
Nagpur
AIIMS Hospital
New Delhi
JIPMER
Puducherry
Sancheti Institute for Orthopaedics and Rehabilitation
Shivājīnagar, 411005
Government Medical Hospital
Trivandrum
Spain7 sites
Hospital San Pau
Barcelona, 08025
Hospital Universitaire Vall d'Hebron
Barcelona, 08035
Corporació Sanitària Parc Taulí
Barcelona, 08208
Mutua de Terrassa Hospital
Barcelona, 08221
Hospital Sant Camil (Consorci Sanitari Garraf)
Barcelona
Costa del Sol
Marbella, 29603
Hospital Clinico Universitario de Vallad
Valladolid
United States5 sites
University of Maryland
Baltimore, Maryland, 20742
Lahey Hospital and Medical Centre
Burlington, Massachusetts, 01805
Ohio State University Medical Centre
Columbus, Ohio, 43210
Regional Medical Center of San Jose
San Jose, California
Tufts Medical Centre
Washington, Massachusetts, 02111
United Kingdom5 sites
Calderdale & Huddersfield NHS
Huddersfield
Chelsea and Westminster Hospital
London, SW10 9NH
West Middlesex Hospital
London
Peterborough City Hospital
Peterborough
King's Mill Hospital
Sutton in Ashfield, NG17 4JL
Italy4 sites
Ospedale San Raffaele
Milan, 20132
Humanitas Research Hospital
Milan
IRCCS Galeazzi Orthopedic Institute
Milan
ASST Sette Laghi - Ospedale Di
Varese
Poland3 sites
SPZOZ Szpital Powiatowy w Bochni im M. Wieckiej
Bochnia
University Hospital & Educational Center of Medical University in Lodz
Lodz
Samodzielny Publiczny Zakład Opieki Zdrowotnej W Myślenicach
Myślenice, 32-400
South Africa3 sites
Groote Schuur Hospital
Cape Town, 7925
Stellenbosch University
Cape Town
Chris Hani Baragwanath Hospital
Johannesburg, 2193
Belgium2 sites
Cliniques Universitaires Saint-Luc
Brussels
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert
France2 sites
Centre Hospitalier Lyon Sud
Lyon
Nimes University Hospital
Nîmes, 30029
Malaysia2 sites
Hospital Pulau Pinang
George Town
University Malaya Medical Centre (UMMC)
Kuala Lumpur, 59100
Pakistan2 sites
Shifa International Hospitals
Islamabad, 44000
The Aga Khan University
Karachi, 74800
About this study
HIP ATTACK is an international randomized controlled trial of 3000 patients with a hip fracture that requires a surgical intervention. This trial will determine the effect of accelerated medical clearance and accelerated surgery compared to standard care on the 90-day risk of mortality and major perioperative complication (i.e., a composite of mortality, nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding).
- Conditions
- Hip Fractures
- Being tested
- Accelerated medical clearance and surgery
- Keywords
- Perioperative outcomes
- Medical subject headings
- Hip Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Accelerated medical clearance and surgeryOther
Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
| Study group | Role | What they receive |
|---|---|---|
| Accelerated medical clearance and surgery | Experimental | Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair. Receives: Other: Accelerated medical clearance and surgery |
| Standard surgical care | No intervention | Surgical hip fracture repair according to the standard timing. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite - major perioperative complication
Composite of mortality, nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding
Measured: 90 days
Mortality
All-cause mortality
Measured: 90 days
Secondary outcomes (40)
All-cause mortality
Death due to all causes
Measured: 90 days and 1 year
Vascular mortality
Death due to vascular cause
Measured: 90 days and 1 year
Non-vascular mortality
Death due to non-vascular cause
Measured: 90 days and 1 year
Myocardial infarction
Myocardial infarction
Measured: 90 days and 1 year
Cardiac revascularization procedure
i.e., percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG] surgery
Measured: 90 days and 1 year
New congestive heart failure
New congestive heart failure
Measured: 90 days and 1 year
New clinically important atrial fibrillation
New clinically important atrial fibrillation
Measured: 90 days
Nonfatal cardiac arrest
Nonfatal cardiac arrest
Measured: 30 days and 1 year
Stroke
Stroke
Measured: 90 days and 1 year
Peripheral arterial thrombosis
Peripheral arterial thrombosis
Measured: 90 days and 1 year
Pulmonary embolism
Pulmonary embolism
Measured: 90 days and 1 year
Deep venous thrombosis
Deep venous thrombosis
Measured: 90 days and 1 year
Pneumonia
Pneumonia
Measured: 90 days and 1 year
Sepsis
Sepsis
Measured: 90 days and 1 year
Infection
Infection
Measured: 90 days
Life-threatening bleeding
Life-threatening bleeding
Measured: 90 days
Major bleeding
Major bleeding
Measured: 90 days
New acute renal failure requiring dialysis
New acute renal failure requiring dialysis
Measured: 90 days and 1 year
Peri-prosthetic fracture
Peri-prosthetic fracture
Measured: 90 days and 1 year
Prosthetic hip dislocation
Prosthetic hip dislocation
Measured: 90 days and 1 year
Implant failure
Implant failure
Measured: 90 days and 1 year
Hip re-operation
Hip re-operation
Measured: 30 days and 1 year
Time to first mobilization
Time to first mobilization
Measured: 90 days
Length of hospital stay
Length of hospital stay
Measured: 90 days
Length of critical care stay
Length of critical care stay
Measured: 90 days
Length of rehabilitation stay
Length of rehabilitation stay
Measured: 90 days
New residence in a nursing home
New residence in a nursing home
Measured: 90 days and 1 year
Functional Independence Measure (FIM™)
Functional Independence Measure (FIM™)
Measured: 30 days and 1 year
SF-36 score
SF-36 score
Measured: 30 days and 1 year
Delirium within 7 days of randomization
Delirium within 7 days of randomization
Measured: 7 days
Hospital readmission
Hospital readmission
Measured: 90 days and 1 year
New pressure ulcers
New pressure ulcers
Measured: 90 days
Incisional pain
Incisional pain
Measured: 30 days
Chronic incisional pain
Chronic incisional pain
Measured: 1 year
Acute Kidney Injury
Acute Kidney Injury
Measured: 90 Day
Acute Kidney Injury
Acute Kidney Injury
Measured: 1 Year
Mortality and Institutionalization status of dependents
Mortality and Institutionalization status of dependents
Measured: 30 Days
Mortality and Institutionalization status of dependents
Mortality and Institutionalization status of dependents
Measured: 1 Year
Economic Analysis
Economic Analysis
Measured: 90 Days and 1 Year
Health System Utilization, Long Term Follow up
Health System Utilization, Long Term Follow up
Measured: 2, 5, 10 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2014 (estimated)
- Study start14 Mar 2014
- Primary completion24 Aug 2019
- Study completion30 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Hip FracturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 3,001 participants (actual)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Collaborators
- Population Health Research Institute, Hamilton Health Sciences Corporation
- Responsible party
- Sponsor
- Investigators
- Philip J Devereaux, MD, PhD, Principal investigator, McMaster UniversityMohit Bhandari, MD, PhD, Principal investigator, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02027896
- Sponsor's protocol ID
- HIP ATTACK Trial v5.0
- Acronym
- HIP ATTACK
- Status last verified
- Jan 2024
- First submitted
- 2 Jan 2014
- Last updated
- 22 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Khan JS, Mulazzani F, Devereaux PJ, Bhandari M, Guerra-Farfan E, Patel A, Shanthanna H, Slobogean G, Sigamani A, Umer M, Feibel RJ, Tiboni ME, Tandon V, Harvey V, Balasubramanian K, Vincent J, Tonelli AC, Gilron I, Torrie AM, Borges FK; HIP ATTACK Investigators. Pain as a Driver of Myocardial Injury in Hip Fracture Patients: A Hip Fracture Accelerated Surgical Treatment and Care Track (HIP ATTACK) Trial Secondary Analysis. Anesthesiology. 2026 Feb 1;144(2):289-300. doi: 10.1097/ALN.0000000000005818. Epub 2025 Oct 27.
PubMed 41147656HIP ATTACK Investigators. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet. 2020 Feb 29;395(10225):698-708. doi: 10.1016/S0140-6736(20)30058-1. Epub 2020 Feb 9.
PubMed 32050090Borges FK, Devereaux PJ, Cuerden M, Bhandari M, Guerra-Farfan E, Patel A, Sigamani A, Umer M, Neary J, Tiboni M, Tandon V, Ramokgopa MT, Sancheti P, John B, Lawendy A, Balaguer-Castro M, Jenkinson R, Sleczka P, Nabi Nur A, Wood GCA, Feibel R, McMahon JS, Sigamani A, Biccard BM, Landoni G, Szczeklik W, Wang CY, Tomas-Hernandez J, Abraham V, Vincent J, Harvey V, Pettit S, Sontrop J, Garg AX; HIP ATTACK investigators. Effects of accelerated versus standard care surgery on the risk of acute kidney injury in patients with a hip fracture: a substudy protocol of the hip fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) international randomised controlled trial. BMJ Open. 2019 Sep 24;9(9):e033150. doi: 10.1136/bmjopen-2019-033150.
PubMed 31551393Borges FK, Bhandari M, Patel A, Avram V, Guerra-Farfan E, Sigamani A, Umer M, Tiboni M, Adili A, Neary J, Tandon V, Sancheti PK, Lawendy A, Jenkinson R, Ramokgopa M, Biccard BM, Szczeklik W, Wang CY, Landoni G, Forget P, Popova E, Wood G, Nabi Nur A, John B, Sleczka P, Feibel RJ, Balaguer-Castro M, Deheshi B, Winemaker M, de Beer J, Kolesar R, Teixidor-Serra J, Tomas-Hernandez J, McGillion M, Shanthanna H, Moppett I, Vincent J, Pettit S, Harvey V, Gauthier L, Alvarado K, Devereaux PJ. Rationale and design of the HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) Trial: a protocol for an international randomised controlled trial evaluating early surgery for hip fracture patients. BMJ Open. 2019 May 1;9(4):e028537. doi: 10.1136/bmjopen-2018-028537.
PubMed 31048449
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial
- ClinicalTrials.gov ID
- NCT02027896
- Acronym / sponsor ID
- HIP ATTACK / HIP ATTACK Trial v5.0
- Conditions
- Hip Fractures
- Keywords
- Perioperative outcomes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,001 participants (actual)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Collaborators
- Population Health Research Institute, Hamilton Health Sciences Corporation
- Study start
- 14 Mar 2014 (actual)
- Primary completion
- 24 Aug 2019 (actual)
- Study completion
- 30 Sep 2022 (actual)
- First posted
- 6 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
HIP ATTACK is an international randomized controlled trial of 3000 patients with a hip fracture that requires a surgical intervention. This trial will determine the effect of accelerated medical clearance and accelerated surgery compared to standard care on the 90-day risk of mortality and major perioperative complication (i.e., a composite of mortality, nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Accelerated medical clearance and surgery | Experimental | Other: Accelerated medical clearance and surgeryRapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair. |
| Standard surgical care | No intervention | –Surgical hip fracture repair according to the standard timing. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- age ≥45 years; and
- diagnosis of hip fracture during working hours with a low-energy mechanism (i.e., falling from standing height) requiring surgery.
Key exclusion criteria (8 listed)
- patients requiring emergent surgery or emergent interventions for another reason (e.g., subdural hematoma, abdominal pathology requiring urgent laparotomy, acute limb ischemia, other fractures or trauma requiring emergent surgery, necrotising fasciitis, coronary revascularization, pacemaker-implantation);
- open hip fracture;
- bilateral hip fractures;
- peri-prosthetic fracture;
- therapeutic anticoagulation not induced by a Vitamin K Antagonist, unfractionated heparin, (e.g., administration of therapeutic Low Molecular Weight Heparin (LMWH) (>6,000 u/24h) in the 24 hours prior to enrolment, or intake of any other non-reversible oral anticoagulant(s) for which there is no reversing agent available
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Accelerated medical clearance and surgeryRapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair. | Other | Accelerated medical clearance and surgery |
Primary outcome
Composite - major perioperative complication
Time frame: 90 days
Composite of mortality, nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding
Mortality
Time frame: 90 days
All-cause mortality
40 secondary outcomes
All-cause mortality
Time frame: 90 days and 1 year
Vascular mortality
Time frame: 90 days and 1 year
Non-vascular mortality
Time frame: 90 days and 1 year
Myocardial infarction
Time frame: 90 days and 1 year
Cardiac revascularization procedure
Time frame: 90 days and 1 year
New congestive heart failure
Time frame: 90 days and 1 year
New clinically important atrial fibrillation
Time frame: 90 days
Nonfatal cardiac arrest
Time frame: 30 days and 1 year
Stroke
Time frame: 90 days and 1 year
Peripheral arterial thrombosis
Time frame: 90 days and 1 year
Pulmonary embolism
Time frame: 90 days and 1 year
Deep venous thrombosis
Time frame: 90 days and 1 year
Pneumonia
Time frame: 90 days and 1 year
Sepsis
Time frame: 90 days and 1 year
Infection
Time frame: 90 days
Life-threatening bleeding
Time frame: 90 days
Major bleeding
Time frame: 90 days
New acute renal failure requiring dialysis
Time frame: 90 days and 1 year
Peri-prosthetic fracture
Time frame: 90 days and 1 year
Prosthetic hip dislocation
Time frame: 90 days and 1 year
Implant failure
Time frame: 90 days and 1 year
Hip re-operation
Time frame: 30 days and 1 year
Time to first mobilization
Time frame: 90 days
Length of hospital stay
Time frame: 90 days
Length of critical care stay
Time frame: 90 days
Length of rehabilitation stay
Time frame: 90 days
New residence in a nursing home
Time frame: 90 days and 1 year
Functional Independence Measure (FIM™)
Time frame: 30 days and 1 year
SF-36 score
Time frame: 30 days and 1 year
Delirium within 7 days of randomization
Time frame: 7 days
Hospital readmission
Time frame: 90 days and 1 year
New pressure ulcers
Time frame: 90 days
Incisional pain
Time frame: 30 days
Chronic incisional pain
Time frame: 1 year
Acute Kidney Injury
Time frame: 90 Day
Acute Kidney Injury
Time frame: 1 Year
Mortality and Institutionalization status of dependents
Time frame: 30 Days
Mortality and Institutionalization status of dependents
Time frame: 1 Year
Economic Analysis
Time frame: 90 Days and 1 Year
Health System Utilization, Long Term Follow up
Time frame: 2, 5, 10 Years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2024.
- Derived from this study: PubMed 41147656Khan JS, Mulazzani F, Devereaux PJ, Bhandari M, Guerra-Farfan E, Patel A, Shanthanna H, Slobogean G, Sigamani A, Umer M, Feibel RJ, Tiboni ME, Tandon V, Harvey V, Balasubramanian K, Vincent J, Tonelli AC, Gilron I, Torrie AM, Borges FK; HIP ATTACK Investigators. Pain as a Driver of Myocardial Injury in Hip Fracture Patients: A Hip Fracture Accelerated Surgical Treatment and Care Track (HIP ATTACK) Trial Secondary Analysis. Anesthesiology. 2026 Feb 1;144(2):289-300. doi: 10.1097/ALN.0000000000005818. Epub 2025 Oct 27.
- Derived from this study: PubMed 32050090HIP ATTACK Investigators. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet. 2020 Feb 29;395(10225):698-708. doi: 10.1016/S0140-6736(20)30058-1. Epub 2020 Feb 9.
- Derived from this study: PubMed 31551393Borges FK, Devereaux PJ, Cuerden M, Bhandari M, Guerra-Farfan E, Patel A, Sigamani A, Umer M, Neary J, Tiboni M, Tandon V, Ramokgopa MT, Sancheti P, John B, Lawendy A, Balaguer-Castro M, Jenkinson R, Sleczka P, Nabi Nur A, Wood GCA, Feibel R, McMahon JS, Sigamani A, Biccard BM, Landoni G, Szczeklik W, Wang CY, Tomas-Hernandez J, Abraham V, Vincent J, Harvey V, Pettit S, Sontrop J, Garg AX; HIP ATTACK investigators. Effects of accelerated versus standard care surgery on the risk of acute kidney injury in patients with a hip fracture: a substudy protocol of the hip fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) international randomised controlled trial. BMJ Open. 2019 Sep 24;9(9):e033150. doi: 10.1136/bmjopen-2019-033150.
- Derived from this study: PubMed 31048449Borges FK, Bhandari M, Patel A, Avram V, Guerra-Farfan E, Sigamani A, Umer M, Tiboni M, Adili A, Neary J, Tandon V, Sancheti PK, Lawendy A, Jenkinson R, Ramokgopa M, Biccard BM, Szczeklik W, Wang CY, Landoni G, Forget P, Popova E, Wood G, Nabi Nur A, John B, Sleczka P, Feibel RJ, Balaguer-Castro M, Deheshi B, Winemaker M, de Beer J, Kolesar R, Teixidor-Serra J, Tomas-Hernandez J, McGillion M, Shanthanna H, Moppett I, Vincent J, Pettit S, Harvey V, Gauthier L, Alvarado K, Devereaux PJ. Rationale and design of the HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) Trial: a protocol for an international randomised controlled trial evaluating early surgery for hip fracture patients. BMJ Open. 2019 May 1;9(4):e028537. doi: 10.1136/bmjopen-2018-028537.
- HIP ATTACK Pilot Canadian Medical Association Journal (CMAJ) PublicationLink provided by the sponsor.
Related trials for Hip Fractures
Enrolling by invitationObservational study
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
Osteoporosis
Not yet recruitingObservational study
3D-Printed Pelvic Models for Planning Complex Total Hip Arthroplasty
Developmental Dysplasia of the Hip, Acetabular Bone Loss
Recruiting
Monitored Anesthesia Care and Soft Tissue Infiltration With Local Anesthesia Feasibility Trial
Hip Fracture Surgeries, Intertrochanteric Fracture
Not yet recruitingPhase 4
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture
Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
Active, not recruitingPhase 2
BDSF Vs DHS With Anterotational Screw in Vertical FNF
Evaluation of BDSF in FNF
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip J Devereaux, MD, PhD principal investigator
McMaster University
Mohit Bhandari, MD, PhD principal investigator
McMaster University
69 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Accelerated medical clearance and surgery in people with Hip Fractures, run by McMaster University at 69 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 69 sites in Canada, India, Spain, United States, United Kingdom and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite - major perioperative complication (time frame: 90 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02027896, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2024.